Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Mark Ragosa Sells 36,372 Shares of Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Mark Ragosa sold 36,372 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $22.25, for a total transaction of $809,277.00. Following the sale, the chief financial officer now directly owns 22,958 shares in the company, valued at approximately $510,815.50. This trade represents a 61.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Kiniksa Pharmaceuticals Price Performance

Shares of Kiniksa Pharmaceuticals stock opened at $22.61 on Friday. The stock has a 50-day simple moving average of $19.95 and a 200-day simple moving average of $22.22. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $16.56 and a 52-week high of $28.15. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -161.49 and a beta of 0.48.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $122.50 million for the quarter, compared to analyst estimates of $123.42 million. During the same quarter last year, the company earned $0.35 EPS. The business’s revenue for the quarter was up 46.9% compared to the same quarter last year. As a group, equities research analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Braidwell LP raised its stake in shares of Kiniksa Pharmaceuticals by 19.3% in the 4th quarter. Braidwell LP now owns 3,452,447 shares of the company’s stock valued at $68,289,000 after acquiring an additional 557,934 shares in the last quarter. Nuveen Asset Management LLC raised its position in shares of Kiniksa Pharmaceuticals by 7.3% in the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company’s stock valued at $15,737,000 after purchasing an additional 54,361 shares during the period. Millennium Management LLC raised its position in shares of Kiniksa Pharmaceuticals by 50.9% in the fourth quarter. Millennium Management LLC now owns 779,672 shares of the company’s stock valued at $15,422,000 after purchasing an additional 263,146 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Kiniksa Pharmaceuticals by 3.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company’s stock worth $15,262,000 after buying an additional 29,300 shares during the period. Finally, Parkman Healthcare Partners LLC grew its stake in Kiniksa Pharmaceuticals by 1.4% in the 4th quarter. Parkman Healthcare Partners LLC now owns 765,453 shares of the company’s stock valued at $15,141,000 after buying an additional 10,209 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

KNSA has been the topic of several recent analyst reports. Citigroup initiated coverage on Kiniksa Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $40.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, February 25th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals currently has an average rating of “Buy” and an average price target of $37.17.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.